Dr. Asad and the team at Universal Neurological Care offer TB006, an investigational drug, to eligible patients through the Expanded Access Program (EAP), a program authorized by the FDA.
TB006 is an investigational drug developed by TrueBinding. In clinical trials, TB006 is currently being evaluated for its potential effects on memory and cognition. TrueBinding’s Phase 2b trial is expected to begin in early 2027. TB006 is experimental and still undergoing clinical testing, and it is not yet FDA approved. Its safety and effectiveness have not been established.
Interested patients or caregivers can contact us to schedule a screening consultation. Our team will:
“Dr. Asad and his team really listen and take the time to understand your condition. You leave feeling cared for and hopeful again.” - Stephen C., a Universal Neurological Care patient
To learn more, visit our TB006 page or call Universal Neurological Care at (904) 404-7044 to schedule a consultation with Dr. Asad.




